Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.04 -0.5%	$2.13	$1.43 ▼ $3.98	$205.84M	1.65	109,799 shs	110,093 shs
CRGX CARGO Therapeutics	$4.47	$4.45	$3.00 ▼ $25.45	$216.17M	0.3	1.73 million shs	N/A
HRTX Heron Therapeutics	$1.35 -2.9%	$1.79	$1.04 ▼ $2.68	$213.08M	1.15	2.57 million shs	1.14 million shs
KPTI Karyopharm Therapeutics	$7.11 -7.4%	$4.81	$3.51 ▼ $16.95	$66.60M	0.28	214,607 shs	132,469 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-0.49%	-5.12%	-6.42%	+17.65%	-35.03%
CRGX CARGO Therapeutics	0.00%	0.00%	0.00%	+5.42%	-73.66%
HRTX Heron Therapeutics	-2.88%	-3.57%	-24.58%	-28.57%	-30.05%
KPTI Karyopharm Therapeutics	-7.42%	+12.86%	+75.56%	+65.35%	-39.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.0028 of 5 stars	3.5	1.0	0.0	3.1	0.8	0.6
CRGX CARGO Therapeutics	2.2026 of 5 stars	2.9	0.0	0.0	2.6	1.7	1.3
HRTX Heron Therapeutics	3.9988 of 5 stars	3.2	1.0	4.2	2.8	3.3	0.6
KPTI Karyopharm Therapeutics	3.9112 of 5 stars	3.4	0.0	4.6	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	488.24% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	244.52% Upside
HRTX Heron Therapeutics	2.33	Hold	$4.50	233.33% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	378.20% Upside

Current Analyst Ratings Breakdown

Latest KPTI, CRGX, ACIU, and HRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$31.02M	6.60	N/A	N/A	$0.90 per share	2.27
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
HRTX Heron Therapeutics	$149.69M	1.38	N/A	N/A	($0.18) per share	-7.50
KPTI Karyopharm Therapeutics	$145.24M	0.42	N/A	N/A	($27.55) per share	-0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-174.94%	-49.35%	-23.16%	11/4/2025 (Estimated)
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	11/11/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	11/11/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)

Latest KPTI, CRGX, ACIU, and HRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/5/2025	Q2 2025	ACIU AC Immune	-$0.20	-$0.25	-$0.05	-$0.25	$1.98 million	$1.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.33	1.33
CRGX CARGO Therapeutics	N/A	12.37	12.37
HRTX Heron Therapeutics	N/A	0.82	0.53
KPTI Karyopharm Therapeutics	N/A	0.99	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
CRGX CARGO Therapeutics	93.16%
HRTX Heron Therapeutics	80.01%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
CRGX CARGO Therapeutics	2.92%
HRTX Heron Therapeutics	5.86%
KPTI Karyopharm Therapeutics	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable

KPTI, CRGX, ACIU, and HRTX Headlines

Recent News About These Companies

139,646 Shares in Karyopharm Therapeutics Inc. $KPTI Acquired by T. Rowe Price Investment Management Inc.

August 28 at 4:51 AM | marketbeat.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 23, 2025 | marketbeat.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rating of "Moderate Buy" by Brokerages

August 21, 2025 | americanbankingnews.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain

August 13, 2025 | msn.com

Karyopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

August 12, 2025 | finanznachrichten.de

Karyopharm Therapeutics: Q2 Earnings Snapshot

August 12, 2025 | chron.com

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

August 11, 2025 | zacks.com

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

August 11, 2025 | seekingalpha.com

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

August 11, 2025 | prnewswire.com

Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect

August 10, 2025 | finance.yahoo.com

Earnings Outlook For Karyopharm Therapeutics

August 8, 2025 | benzinga.com

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

August 5, 2025 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 29, 2025 | zacks.com

JPMorgan Chase & Co. Expands Stake in Karyopharm Therapeutics Inc.

July 22, 2025 | gurufocus.com

HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI)

July 16, 2025 | msn.com

Karyopharm stock tumbles after disclosing failed financing talks

July 11, 2025 | investing.com

Karyopharm lays off more workers as hunt for strategic alternatives turns up short

July 11, 2025 | fiercebiotech.comF

Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway

July 11, 2025 | msn.com

Karyopharm to Cut About 20% of Workforce Amid Ongoing Review

July 11, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, CRGX, ACIU, and HRTX Company Descriptions

AC Immune NASDAQ:ACIU

$2.04 -0.01 (-0.49%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.07 +0.03 (+1.47%)

As of 08/29/2025 07:43 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

CARGO Therapeutics NASDAQ:CRGX

$4.47 0.00 (0.00%)

As of 08/19/2025

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Heron Therapeutics NASDAQ:HRTX

$1.35 -0.04 (-2.88%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.02 (+1.85%)

As of 08/29/2025 07:17 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Karyopharm Therapeutics NASDAQ:KPTI

$7.11 -0.57 (-7.42%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.09 -0.02 (-0.34%)

As of 08/29/2025 07:22 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time